cagrilintide semaglutide phase 2 weight loss CagriSema in Adults With or Without Diabetes – REDEFINE 1 & • 💊 2.4 mg + 2.4 mg once weekly • 📉 –20.4% (non-diabetic) & –13.7% (T2D) In the REDEFINE 2 phase

In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results 1 CagriSema 2.4 mg 2.4 mg FDA NDA filing; Novo Nordisk data on file., 2 Garvey WT, Blher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or CagriSema (CagrilintideSemaglutide) in Adults with Overweight or Obesity and Type 2 Diabetes Headlands Research REDEFINE 1 Trial Finds CagrilintideSemaglutide Combo Delivers Over 20% Weight Loss in Majority of Patients Applied Clinical Trials Online

SKU: 91320180357 · From astonvaughan.co.uk